Search

Your search keyword '"Corasaniti MT"' showing total 201 results

Search Constraints

Start Over You searched for: Author "Corasaniti MT" Remove constraint Author: "Corasaniti MT"
201 results on '"Corasaniti MT"'

Search Results

1. Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence

2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)

3. Neuropharmacology of the neuropsychiatric symptoms of dementia: possible targets for novel therapeutic approaches

4. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy

5. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).

9. Cell signaling pathways in the mechanisms of neuroprotection afforded by bergamot essential oil against NMDA-induced cell death in vitro

10. Identification of transglutaminase 3 splicing isoforms [9]

11. Evidence implicating matrix metalloproteinases in the mechanism underlying accumulation of IL-1beta and neuronal apoptosis in the neocortex of HIV/gp120-exposed rats

16. Apoptosis induced by gp120 in the neocortex of rat involves enhanced expression of cyclooxygenase type 2 (COX-2) and is prevented by NMDA receptor antagonists and by the 21-aminosteroid U-74389G

22. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

24. The Antidepressant Drug Amitriptyline Affects Human SH-SY5Y Neuroblastoma Cell Proliferation and Modulates Autophagy.

25. Clinical and Market Analysis of NanoBEO: A Public-Worth, Innovative Therapy for Behavioral and Psychological Symptoms of Dementia (BPSD)-Emerging Evidence and Its Implications for a Health Technology Assessment (HTA) and Decision-Making in National Health Systems.

26. Efficacy of therapeutic intervention with NanoBEO to manage agitation and pain in patients suffering from severe dementia: a pilot clinical trial.

27. Motor behavior induced by bergamot essential oil in experimental tasks is differentially modulated by pretreatment with metabotropic glutamate receptor 2/3 or 5 antagonists.

29. Exploitation of Autophagy Inducers in the Management of Dementia: A Systematic Review.

30. Combination of anti-CGRP/CGRP-R mAbs with onabotulinumtoxin A as a novel therapeutic approach for refractory chronic migraine: a retrospective study of real-world clinical evidence and a protocol for a double-blind, randomized clinical trial to establish the efficacy and safety.

31. Effect of genotype on individual response to the pharmacological treatment of glaucoma: a systematic review and meta-analysis.

32. Antiseizure Medications in Alzheimer's Disease from Preclinical to Clinical Evidence.

33. Safety of Onabotulinumtoxin A in Chronic Migraine: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

34. Efficacy of Essential Oils in Relieving Cancer Pain: A Systematic Review and Meta-Analysis.

35. Focus on zavegepant: the first intranasal third-generation gepant.

36. NAbiximols Clinical Translation To the treatment of Pain and Agitation In Severe Dementia (NACTOPAISD): Clinical trial protocol.

37. Effects of Palmitoylethanolamide (PEA) on Nociceptive, Musculoskeletal and Neuropathic Pain: Systematic Review and Meta-Analysis of Clinical Evidence.

38. Analgesic Characteristics of NanoBEO Released by an Airless Dispenser for the Control of Agitation in Severe Dementia.

39. Transgenic Mice for the Translational Study of Neuropathic Pain and Dystonia.

40. Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine.

41. Pain and agitation treatment in severe dementia patients: The need for Italian Mobilization-Observation-Behavior-Intensity-Dementia (I-MOBID2) pain scale translation, adaptation and validation with psychometric testing.

42. Translational Value of the Transdermal Administration of Bergamot Essential Oil and of Its Fractions.

43. Pharmacological Treatment of Pain and Agitation in Severe Dementia and Responsiveness to Change of the Italian Mobilization-Observation-Behavior-Intensity-Dementia (I-MOBID2) Pain Scale: Study Protocol.

44. Antispasmodic Effect of Bergamot Essential Oil on Rat Isolated Gut Tissues.

45. Real world considerations for newly approved CGRP receptor antagonists in migraine care.

46. Dementia and COVID-19: A Case Report and Literature Review on Pain Management.

47. Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence.

48. Preclinical Characterization of Antinociceptive Effect of Bergamot Essential Oil and of Its Fractions for Rational Translation in Complementary Therapy.

49. Requirements for Translation in Clinical Trials of Aromatherapy: The Case of the Essential Oil of Bergamot (BEO) for Management of Agitation in Severe Dementia.

50. New trends in pharmacological control of neuropsychiatric symptoms of dementia.

Catalog

Books, media, physical & digital resources